Michigan High Throughput Screening Center and NSF International Announce Partnership
News Aug 01, 2007
MHTSC is a not-for-profit, contract research laboratory that provides assay development and high throughput screening (HTS) services without licensing fees or royalties. Through the new partnership, pharmaceutical companies and biotechnology companies can now take advantage of HTS screening offered by MHTSC and high content screening offered by GLS – capabilities that are critical in drug development and research.
“As more and more drug companies outsource their research and testing, our goal is to provide solutions that will expedite the drug development process,” said Aline Lindbeck, Ph.D., general manager, Global Lifescience Solutions. “Our life-science organizations and state-of-the-art laboratories will position the State of Michigan as a leader in scientific research and high-tech screening services.”
Together, GLS and MHTSC will assist companies in identifying potential leads for drug discovery. GLS’ high content screening services provide preliminary toxicity data on drug candidates as well as additional information on the mechanisms by which drug candidates may elicit their cellular response.
Companies that will benefit from the new collaboration include public research institutions, government institutions, and biotechnology and pharmaceutical companies that conduct drug discovery work, as well as companies who do not have in-house high content or high throughput screening capabilities.
“Our mission at MHTSC is to provide access to state of the art screening technology and expertise,” said Rob Kilkuskie, Ph.D., senior director, Michigan High Throughput Screening Center. “Our collaboration with GLS allows us to expand the characterization of the compounds coming out of our screens. We believe this will greatly facilitate our clients’ drug discovery research.”
New service offerings under the partnership include:
• Prescreening services – help companies determine which targets should be fully screened
• Assay development – assay design and optimization
• Follow-up services – assist companies with follow-up screening and lead optimization
• High content screening – help companies examine multiple cellular targets and parameters in a large number of individually imaged cells and quantitatively assess the data
“The collaboration between GLS and MHTSC leverages the expertise and technology at each institution, and provides our clients an expanded array of screening services,” said Kathy Johnson, director of business development, MHTSC.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE